Advaxis Inc (NASDAQ:ADXS)’s Stock Is Buy After Less Market Selling

Advaxis, Inc. (NASDAQ:ADXS) Logo

The stock of Advaxis Inc (NASDAQ:ADXS) registered a decrease of 6.3% in short interest. ADXS’s total short interest was 2.27M shares in July as published by FINRA. Its down 6.3% from 2.42 million shares, reported previously. With 688,900 shares average volume, it will take short sellers 3 days to cover their ADXS’s short positions.

The stock increased 0.97% or $0.015 during the last trading session, reaching $1.565. About 128,388 shares traded. Advaxis, Inc. (NASDAQ:ADXS) has declined 88.72% since July 14, 2018 and is downtrending. It has underperformed by 93.15% the S&P500.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The company has market cap of $12.55 million. The Company’s lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer. It currently has negative earnings. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.

More notable recent Advaxis, Inc. (NASDAQ:ADXS) news were published by: Seekingalpha.com which released: “Advaxis, Inc. (ADXS) CEO Kenneth Berlin on Q2 2019 Results – Earnings Call Transcript – Seeking Alpha” on June 11, 2019, also Nasdaq.com with their article: “Advaxis (ADXS) Upgraded to Buy: Here’s What You Should Know – Nasdaq” published on February 20, 2019, Nasdaq.com published: “Health Care Sector Update for 04/03/2019: SWAV,EVGN,ADXS – Nasdaq” on April 03, 2019. More interesting news about Advaxis, Inc. (NASDAQ:ADXS) were released by: Benzinga.com and their article: “44 Stocks Moving In Monday’s Mid-Day Session – Benzinga” published on June 17, 2019 as well as Seekingalpha.com‘s news article titled: “FDA halts recruitment in Advaxis late-stage study of AXAL in cervical cancer – Seeking Alpha” with publication date: January 23, 2019.

Advaxis, Inc. (NASDAQ:ADXS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.